CC BY-NC-ND 4.0 · AJP Rep 2024; 14(01): e22-e25
DOI: 10.1055/s-0043-1777998
Case Report

Small Cell Cervical Carcinoma in Pregnancy: Therapeutic Options for an Aggressive Cancer Diagnosis

1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
Zeinab Kassem
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
,
Margarita de Veciana
1   Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia
› Author Affiliations

Abstract

Neuroendocrine small cell cervical carcinoma is an aggressive cancer which accounts for approximately 1 to 3% of all cervical neoplasms. Therapy must be altered in pregnancy to optimize maternal–fetal outcomes. A 39-year-old woman presented for a routine prenatal visit and was noted to have a grossly abnormal cervix. Cervical biopsies confirmed small cell carcinoma. At 19 weeks' gestation, chemotherapy was initiated. The patient delivered at 34 weeks' gestation to initiate radiation therapy. Six months later, she was diagnosed with metastatic disease and died from cancer complications. In pregnancy, treatment modalities for small cell cervical carcinoma are based on the patient's gestational age at diagnosis. While aggressive early treatment is preferred, platinum-based chemotherapy can be initiated in the second trimester and radiation therapy delayed until delivery. Small cell cervical carcinoma complicating pregnancy requires aggressive treatment. Chemotherapy in the second trimester with planned delayed radiation therapy, may optimize fetal outcomes.



Publication History

Received: 31 December 2020

Accepted: 22 October 2023

Article published online:
23 January 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Delaloge S, Pautier P, Kerbrat P. et al. Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. Clin Oncol (R Coll Radiol) 2000; 12 (06) 357-362
  • 2 Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol 2011; 122 (01) 190-198
  • 3 Liao LM, Zhang X, Ren YF. et al. Chromogranin A (CgA) as poor prognostic factor in patients with small cell carcinoma of the cervix: results of a retrospective study of 293 patients. PLoS One 2012; 7 (04) e33674
  • 4 Ohwada M, Suzuki M, Hironaka M, Irie T, Sato I. Neuroendocrine small cell carcinoma of the uterine cervix showing polypoid growth and complicated by pregnancy. Gynecol Oncol 2001; 81 (01) 117-119
  • 5 Pan L, Liu R, Sheng X, Chen D. Small cell neuroendocrine carcinoma of the cervix in pregnancy: a case report and review. Case Rep Obstet Gynecol 2019; 8028459
  • 6 Teefey P, Orr B, Vogt M, Roberts W. Neuroendocrine carcinoma of the cervix during pregnancy: a case report. Gynecol Oncol Case Rep 2012; 2 (03) 73-74
  • 7 Cohen JG, Kapp DS, Shin JY. et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol 2010; 203 (04) 347.e1-347.e6
  • 8 English DP, Roque DM, Carrara L. et al. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol 2013; 131 (03) 753-758
  • 9 McCusker ME, Coté TR, Clegg LX, Tavassoli FJ. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol 2003; 88 (03) 333-339
  • 10 Morris M, Gershenson DM, Eifel P, Silva EG, Mitchell MF, Burke TW, Wharton JT. Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposide. Gynecol Oncol 1992; 47 (01) 62-65 DOI: 10.1016/0090-8258(92)90077-v. . PMID: 1330847
  • 11 Li JD, Zhuang Y, Li YF. et al. A clinicopathological aspect of primary small-cell carcinoma of the uterine cervix: a single-centre study of 25 cases. J Clin Pathol 2011; 64 (12) 1102-1107
  • 12 Masumoto N, Fujii T, Ishikawa M. et al. P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol 2003; 34 (08) 778-783
  • 13 Lee JM, Lee KB, Nam JH. et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol 2008; 19 (02) 321-326
  • 14 Nagao S, Miwa M, Maeda N. et al. Clinical features of neuroendocrine carcinoma of the uterine cervix: a single-institution retrospective review. Int J Gynecol Cancer 2015; 25 (07) 1300-1305
  • 15 Leitao M, Zivanovic O. Small cell neuroendocrine carcinoma of the cervix. In: Post TW, ed. Waltham, MA: UpToDate; 2020
  • 16 Balderston KD, Tewari K, Gregory WT, Berman ML, Kucera PR. Neuroendocrine small cell uterine cervix cancer in pregnancy: long-term survival following combined therapy. Gynecol Oncol 1998; 71 (01) 128-132
  • 17 Wang Q, Liu YH, Xie L, Hu WJ, Liu BR. Small cell carcinoma of the uterine cervix in pregnancy: a case report and review of the literature. Oncol Lett 2015; 9 (01) 91-95
  • 18 Mir O, Berveiller P, Ropert S, Goffinet F, Goldwasser F. Use of platinum derivatives during pregnancy. Cancer 2008; 113 (11) 3069-3074
  • 19 Chen J, Macdonald OK, Gaffney DK. Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix. Obstet Gynecol 2008; 111 (06) 1394-1402